---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-050922"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:19:29.155291+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Syndax revumenib meets primary endpoint in pivotal AUGMENT-101 trial; CR/CRh 23% (p=0.0036)

## Summary
- Primary endpoint met with CR/CRh 23% (13/57) in pooled KMT2Ar acute leukemia; p=0.0036.
- 65% overall response rate in KMT2Ar AML; 50% of transplanted patients received post-transplant revumenib.
- Median duration of CR/CRh 6.4 months; 46% still in remission as of July 24, 2023.
- Favorable safety: only 6% discontinued due to TRAEs; no discontinuations for DS or QTc prolongation.
- Company to submit NDA for revumenib to FDA by year-end; funded into 2025.

## SEC filing metadata
- accession: 0000950170-23-050922
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017023050922/0000950170-23-050922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017023050922/sndx-20231002.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-050922
- JSON: https://secwatch.observer/filing/0000950170-23-050922.json
- Plain text: https://secwatch.observer/filing/0000950170-23-050922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.